• Kristin J Meyers, Brian Dillman, Charles Williams, Jianfei Jiang, Nancy Clifford, Jennifer L Miller, Meghan E Jones, Iris A Goetz, Fady T Botros, Jack Knorr, David H Manner, and Brad Woodward.
• Lilly Research Labs, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA.
• J. Med. Virol. 2021 May 1; 93 (5): 2925-2931.

AbstractA nested longitudinal study within theAsymptomatic novel CORonavirus iNFfection study followed participants with positive nasopharyngeal swab to query for development of symptoms and assess duration of positive reverse transcription-polymerase chain reaction (RT-PCR) test results. Of the 91 participants initially testing positive, 86 participated in follow-up approximately 14 days after study enrollment; of those 86 participants, 19 (22.1%) developed at least one symptom at any time after the initial positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result. The median number of days to symptom development after their initial positive test result was 6 (range 1-29 days). No participants reported a SARS-CoV-2-related hospitalization. The most frequently reported symptoms were fatigue or muscle aches (10.5%), headache (9.3%), fever (5.8%), and shortness of breath (5.8%). Of the 78 participants who submitted a nasopharyngeal swab for repeat RT-PCR testing, 17 (21.8%) remained positive at Day 14, 4 of which continued to test positive at Day 28. These findings reinforce the probable role of silent SARS-CoV-2 infections in community transmission, and that reliance on symptom development will miss a large proportion of infections. Broad testing programs not limited to individuals presenting with symptoms are critical for identifying persons with SARS-CoV-2 infection and ultimately slowing transmission.© 2021 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC.

38 keywords...

hide…